Do SARS-CoV-2 Variants Differ in Their Neuropathogenicity?
mBio · 28.02.2023 · 14 (1)
DOI: 10.1128/mbio.02920-22 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, erschienen am 28.02.2023. Verfasst von Lisa Bauer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: COVID-19, Nervous System Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.
Abstract (Originalsprache)
Neurological complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are a huge societal problem. Although the neuropathogenicity of SARS-CoV-2 is not yet fully understood, there is evidence that SARS-CoV-2 can invade and infect cells of the central nervous system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands.
ORCID-Profile: Lisa Bauer, Debby van Riel
Förderung
- ZonMw
Zitieren
APA
Bauer, L., & van Riel, D. (2023). Do SARS-CoV-2 Variants Differ in Their Neuropathogenicity?. mBio, 14(1). https://doi.org/10.1128/mbio.02920-22
Vancouver
Bauer L, van Riel D. Do SARS-CoV-2 Variants Differ in Their Neuropathogenicity?. mBio. 2023;14(1). doi:10.1128/mbio.02920-22
BibTeX
@article{Bauer2023,
author = {Bauer, Lisa and van Riel, Debby},
title = {Do SARS-CoV-2 Variants Differ in Their Neuropathogenicity?},
journal = {mBio},
year = {2023},
volume = {14},
number = {1},
doi = {10.1128/mbio.02920-22}
}
EUVIMED